News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
508,561 Results
Type
Article (37196)
Company Profile (150)
Press Release (471215)
Section
Business (151106)
Career Advice (1545)
Deals (29070)
Drug Delivery (105)
Drug Development (71042)
Employer Resources (125)
FDA (11950)
Job Trends (11401)
News (270379)
Policy (29679)
Tag
2024 BioCapital Digital (9)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (4)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (3)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (1954)
Accelerated approval (1)
Adcomms (21)
Allergies (64)
Alliances (46614)
ALS (66)
Alzheimer's disease (1150)
Antibody-drug conjugate (ADC) (94)
Approvals (11930)
Artificial intelligence (170)
Autoimmune disease (10)
Automation (8)
Bankruptcy (272)
Best Places to Work (8913)
BIOSECURE Act (18)
Biosimilars (82)
Biotechnology (77)
Bladder cancer (43)
Brain cancer (26)
Breast cancer (181)
Cancer (1471)
Cardiovascular disease (110)
Career advice (1296)
Career pathing (21)
CAR-T (103)
Cell therapy (293)
Cervical cancer (12)
Clinical research (57391)
Collaboration (648)
Compensation (331)
Complete response letters (24)
COVID-19 (2520)
CRISPR (30)
C-suite (138)
Cystic fibrosis (71)
Data (1363)
Decentralized trials (1)
Denatured (20)
Depression (33)
Diabetes (197)
Diagnostics (4042)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (35)
Drug discovery (87)
Drug pricing (104)
Drug shortages (29)
Duchenne muscular dystrophy (61)
Earnings (55250)
Editorial (30)
Employer branding (17)
Employer resources (112)
Events (68517)
Executive appointments (439)
FDA (12717)
Featured Employer (34)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (4)
Funding (459)
Gene editing (70)
Generative AI (14)
Gene therapy (231)
GLP-1 (695)
Government (4279)
Grass and pollen (3)
Guidances (33)
Healthcare (12644)
Huntington's disease (18)
IgA nephropathy (20)
Immunology and inflammation (69)
Indications (21)
Infectious disease (2639)
Inflammatory bowel disease (100)
Inflation Reduction Act (8)
Influenza (43)
Intellectual property (65)
Interviews (267)
IPO (12500)
IRA (44)
Job creations (2909)
Job search strategy (1127)
Kidney cancer (7)
Labor market (12)
Layoffs (349)
Leadership (9)
Legal (7826)
Liver cancer (56)
Lung cancer (212)
Lymphoma (102)
Machine learning (2)
Management (38)
Manufacturing (230)
MASH (51)
Medical device (6511)
Medtech (6514)
Mergers & acquisitions (16920)
Metabolic disorders (552)
Multiple sclerosis (47)
NASH (21)
Neurodegenerative disease (62)
Neuropsychiatric disorders (22)
Neuroscience (1521)
NextGen: Class of 2025 (4302)
Non-profit (3011)
Northern California (1583)
Now hiring (9)
Obesity (316)
Opinion (213)
Ovarian cancer (49)
Pain (56)
Pancreatic cancer (59)
Parkinson's disease (101)
Partnered (9)
Patents (156)
Patient recruitment (52)
Peanut (38)
People (41024)
Pharmaceutical (71)
Pharmacy benefit managers (16)
Phase I (17165)
Phase II (25148)
Phase III (19794)
Pipeline (684)
Podcasts (65)
Policy (105)
Postmarket research (2243)
Preclinical (7115)
Press Release (42)
Prostate cancer (73)
Psychedelics (30)
Radiopharmaceuticals (230)
Rare diseases (284)
Real estate (4091)
Recruiting (53)
Regulatory (19264)
Reports (21)
Research institute (1820)
Resumes & cover letters (226)
Rett syndrome (1)
RNA editing (1)
RSV (41)
Schizophrenia (63)
Series A (82)
Series B (41)
Service/supplier (6)
Sickle cell disease (43)
Southern California (1368)
Special edition (8)
Sponsored (20)
Startups (2664)
State (2)
Stomach cancer (13)
Supply chain (55)
The Weekly (44)
United States (13751)
Vaccines (666)
Venture capitalists (24)
Webinars (11)
Weight loss (246)
Women's health (16)
Worklife (8)
Date
Today (148)
Last 7 days (620)
Last 30 days (2224)
Last 365 days (26300)
2025 (4256)
2024 (26845)
2023 (30164)
2022 (39764)
2021 (42682)
2020 (40781)
2019 (33740)
2018 (25784)
2017 (25546)
2016 (24373)
2015 (28200)
2014 (22328)
2013 (18495)
2012 (19699)
2011 (20398)
2010 (18736)
Location
Africa (692)
Alabama (36)
Alaska (3)
Arizona (106)
Arkansas (8)
Asia (33917)
Australia (5398)
California (3575)
Canada (1379)
China (352)
Colorado (166)
Connecticut (173)
Delaware (89)
Europe (75023)
Florida (557)
Georgia (110)
Hawaii (1)
Idaho (32)
Illinois (326)
India (19)
Indiana (204)
Iowa (4)
Japan (112)
Kansas (73)
Kentucky (16)
Louisiana (7)
Maine (27)
Maryland (642)
Massachusetts (2726)
Michigan (112)
Minnesota (162)
Mississippi (1)
Missouri (50)
Montana (23)
Nebraska (12)
Nevada (39)
New Hampshire (25)
New Jersey (1130)
New Mexico (17)
New York (1054)
North Carolina (629)
North Dakota (4)
Northern California (1583)
Ohio (120)
Oklahoma (7)
Oregon (22)
Pennsylvania (798)
Puerto Rico (6)
Rhode Island (13)
South America (997)
South Carolina (5)
South Dakota (1)
Southern California (1368)
Tennessee (53)
Texas (480)
Utah (90)
Virginia (98)
Washington D.C. (41)
Washington State (317)
West Virginia (2)
Wisconsin (27)
508,561 Results for "aop orphan pharmaceuticals ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results
AOP Orphan Pharmaceuticals GmbH continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association 2024 hybrid congress in Madrid, Spain.
June 10, 2024
·
6 min read
Press Releases
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
February 17, 2025
·
4 min read
Press Releases
U.S. FDA Approves AOP Health’s RapiblykTM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
November 27, 2024
·
8 min read
Press Releases
Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells
October 1, 2024
·
3 min read
Press Releases
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
December 19, 2024
·
11 min read
Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia
AOP Orphan Pharmaceuticals GmbH announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera in the prestigious journal Leukemia.
September 19, 2023
·
4 min read
Biotech Beach
Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting
AOP Orphan Pharmaceuticals GmbH announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythaemia vera 1 These new data show that some low-risk PV patients require and can tolerate high ropeginterferon alfa-2b doses, and that the optimal dose varies substantially between patients.
December 7, 2023
·
3 min read
Press Releases
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)
November 20, 2024
·
5 min read
Press Releases
iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis
February 13, 2025
·
1 min read
Press Releases
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
September 11, 2024
·
5 min read
1 of 50,857
Next
